PASG
Passage Bio·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 1
Consensus Rating "Strong Buy"
Ample Liquidity
EPS Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PASG
Passage Bio, Inc.
A clinical-stage genetic medicines company that develops therapies for the treatment of rare monogenic central nervous system diseases
Biological Technology
07/26/2017
02/28/2020
NASDAQ Stock Exchange
60
12-31
Common stock
One Commerce Square
, 2005 Market Street
, 39th Floor
, Philadelphia
, PA 19103
--
Passage Bio, Inc., a Delaware-based company founded on July 26, 2017, is a genetic medicine company focused on the development of translational therapies for rare single-gene central nervous system diseases. Its vision is to become a leading genetic medicine company and actively change the lives of patients whose lives are threatened by these diseases.
Company Financials
EPS
PASG has released its 2025 Q3 earnings. EPS was reported at -2.44, versus the expected -2.97, beating expectations. The chart below visualizes how PASG has performed over recent quarters, highlighting trends in earnings surprises.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
